SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-22-123918
Filing Date
2022-04-27
Accepted
2022-04-27 17:16:17
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A d353949ddefa14a.htm DEFA14A 23552
2 GRAPHIC g353949s4.jpg GRAPHIC 44033
3 GRAPHIC g353949snap0001.jpg GRAPHIC 1826
4 GRAPHIC g353949snap0006.jpg GRAPHIC 912
5 GRAPHIC g353949sp03.jpg GRAPHIC 28663
  Complete submission text file 0001193125-22-123918.txt   129184
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36483 | Film No.: 22860946
SIC: 8071 Services-Medical Laboratories